Oral Antidiabetic Drugs for Cats

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 23, Issue 7, 2001, Pages 633-641

  Cowan, Sara M ^a   Bunch, Susan E ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FELIS CATUS;

EID: 0347664832     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Feldman EC, Nelson RW: Diabetes mellitus, in Feldman EC, Nelson RW (eds): Canine and Feline Endocrinology and Reproduction, ed 2. Philadelphia, WB Saunders Co, 1996, pp 339-391.
2. Kirk CA, Feldman EC, Nelson RW: Diagnosis of naturally acquired type-I and type-II diabetes mellitus in cats. Am J Vet Res 54:463-467, 1993.
3. Nelson RW, Griffey SM, Feldman EC, Ford SL: Transient clinical diabetes mellitus in cats: 10 Cases (1989-1991). J Vet Intern Med 13:28-35, 1999.
4. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: A balanced overview. Diabetes Care 15:318-368, 1992.
5. Pimenta W, Korytkowski M, Mitra A, et al: Pancreatic B-cell dysfunction as the primary genetic lesion in NIDDM. JAMA 273:1855-1861, 1995.
6. Johnson KH, O'Brien TD, Betsholtz C, Westermark P: Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 321:513-518, 1989.
7. Turner RC, Cull CA, Frighi V, Homan RR: The UK Prospective Diabetes Study Group (UKPDS). JAMA 281:2005-2012, 1999.
8. Rubin RJ, Altman WM, Mendelson DN: Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 78:809, 1994.
9. Melander A: Clinical pharmacology of sulfonylureas. Metabolism 28:12-16, 1987.
10. Bressler R, Johnson DG: Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 157:836-848, 1997.
11. Malaisse WJ, Lebrun P: Mechanism of sulfonylurea-induced insulin release. Diabetes Care 13:9-17, 1990.
12. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303, 1999.
13. Lebovitz HE, Melander A: Sulfonylureas: Basic aspects and clinical uses, in Alberti KG, Zimmet P, DeFronzo RA (eds): International Textbook of Diabetes Mellitus, ed 2. New York, J Wiley, 1997, pp 817-840.
14. Blaum CS, Velez L, Hiss RG, Halter JB: Characteristics related to poor glycemic control in type II DM patients in community practice. Diabetes Care 20:7-11, 1997.
15. Miller AB, Nelson RW, Kirk CA, et al: Effect of glipizide on serum insulin and glucose concentrations in healthy cats. Res Vet Sci 52:177-181, 1992.
16. 16a. Nelson RW, Feldman EC, Ford SL, Roemer OP: Effect of an orally administered sulfonylurea, glipizide, for treatment of diabetes mellitus in cats. JAVMA 203:821-827, 1993.
17. 16b. Feldman EC, Nelson RW, Feldman MS: Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus. JAVMA 210:772-777, 1997.
18. Garcia JL, Bruyette DS: Using oral hypoglycemic agents to treat diabetes mellitus in cats. Vet Med 736-742, 1998.
19. th ACVIM Forum:252-254, 1997.
20. Behrend EN, Greco DS: Treatment of feline diabetes mellitus: Overview and therapy. Compend Contin Educ Pract Vet 22:423-438, 2000.
21. Heine RJ: Role of sulfonylureas in NIDDM: Part II - The cons. Horm Metab Res 28:522-526, 1996.
22. Lebovitz HE, Melander A: Sulfonylureas: Basic aspects and clinical uses, in Alberti KG, Zimmet P, DeFronzo RA (eds): International Textbook of Diabetes Mellitus, ed 2. New York, J Wiley, 1997, pp 745-772.
23. Seltzer HS: Drug-induced hypoglycemia: A review of 1418 cases. Endocrinol Metab Clin North Am 18:163-183, 1989.
24. Bailey CJ, Day C: Traditional plant medicines as treatments for diabetes. Diabetes Care 12:553-564, 1989.
25. Michels GM, Boudinot FD, Ferguson DC, Hoenig M: Pharmacokinetics of the antihyperglycemic agent metformin in cats. Am J Vet Res 60:738-742, 1999.
26. th ACVIM Forum:722, 2000.
27. Baily CJ, Turner RC: Metformin. N Engl J Med 334: 574-578, 1996.
28. Stumvoll M, Nurjhan N, Perriello G, et al: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995.
29. Melchior WR, Jaber LA: Metformin: An antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother 30:158-164, 1996.
30. Johansen K: Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22:33-37, 1999.
31. Aviles SL, Sindling J, Raskin P: Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:182-188, 1999.
32. Groop LC, Bonadonna RC, Del Prato S, et al: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213, 1989.
33. Kuehnle HF: New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes 104:93-101, 1996.
34. Loi CM, Young M, et al: Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104, 1999.
35. Wagenaar LJ, Kuck EM, Hoekstra JB: Troglitazone. Is it all over? Neth J Med 55:4-12, 1999.
36. Plosker GL, Faulds D: Troglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 57:409-438, 1999.
37. Davies GF, Khandelwal RL, Roesler WJ: Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Biochim Biophys Acta 1451:122-131, 1999.
38. Buysschaert M, Bobbioni E, Starkie M, Frith L: Troglitazone in combination with sulfonylurea improves glycemic control in Type 2 diabetic patients inadequately controlled by sulfonylurea therapy alone. Troglitazone Study Group. Diabetes Med 16:147-153, 1999.
39. Hirsch IB, Kelly J, Cooper S: Pulmonary edema associated with troglitazone therapy [letter]. Arch Intern Med 159: 1811, 1999.
40. Fukano M, Amano S, et al: Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: A case report with autopsy examination. Human Pathol 31:250-253, 2000.
41. Robertson J, Nelson R, Kass P, Neal L: Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs. Am J Vet Res 60:541-545, 1999.
42. th ACVIM Forum:722, 2000.
43. Kelley DE, Bidot P, Freedman Z, et al: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 21:2056-2061, 1998.
44. Vierhapper H, Bratusch-Marrain A, Waldausl W: Alpha-glucoside hydrolase inhibition in diabetes. Lancet 2:1386, 1978.
45. Walton RJ, Sherif IT, Noy GA, et al: Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor. BMJ 1:220-221, 1979.
46. Coniff RF, et al: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18:928-932, 1995.
47. Holamn RR, Cull CA, Turner RC: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22:960-964, 1999.
48. Mertes G: Efficacy and safety of acarbose in the treatment of type 2 diabetes: Data from a 2-year surveillance study. Diabetes Res Clin Pract 40:63-70, 1998.
49. Mooradian AD, Albert SG, et al: Dose-response profile of acarbose in older subjects with type 2 diabetes. Am J Med Sci 319(5):334-337, 2000.
50. Chiasson JL, Josse RG, Hunt JA, et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121:928-935, 1994.
51. Scheen AJ: Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials. Diabetes Metab 24: 311-320, 1998.
52. Hanefeld M: The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:228-237, 1998.
53. Odawara M, Bannai C, Saitoh T, et al: Potentially lethal ileus associated with acarbose treatment for NIDDM [letter]. Diabetes Care 20:1210-1211, 1997.
54. Scorpiglione N, Belfiglio M, Carinci F, et al: The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. Eur J Clin Pharmacol 55:239-249, 1999.
55. Riccardi G, Giacco R, Parillo M, et al: Efficacy and safety of acarbose in the treatment of type I diabetes mellitus: A placebo-controlled, double-blind, multicentre study. Diabetes Med 16:228-232, 1999.
56. Ranganath L, Norris F, Morgan L, et al: Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its antihyperglycemic effect. Diabetes Med 15:120-124, 1998.
57. Nelson RW, Feldman EC: Complications associated with insulin treatment of diabetes mellitus, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy XIII. Philadelphia, WB Saunders Co, 1999, pp 354-357.
58. Greco DS: Treatment of non-insulin-dependent diabetes mellitus in cats using oral hypoglycemic agents, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy XIII. Philadelphia, WB Saunders Co, 1999, pp 350-354.
59. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 17:616-623, 1994.
60. Buse J: Combining insulin and oral agents. Am J Med 108 (Suppl 6a):235-325, 2000.